[go: up one dir, main page]

CL2008000442A1 - Composicion farmaceutica que comprende a un quitosano, un ingrediente activo cosmetico o farmaceutico, y un solvente volatil; y su uso para tratar psoriasis, micosis entre otras enfermedades. - Google Patents

Composicion farmaceutica que comprende a un quitosano, un ingrediente activo cosmetico o farmaceutico, y un solvente volatil; y su uso para tratar psoriasis, micosis entre otras enfermedades.

Info

Publication number
CL2008000442A1
CL2008000442A1 CL200800442A CL2008000442A CL2008000442A1 CL 2008000442 A1 CL2008000442 A1 CL 2008000442A1 CL 200800442 A CL200800442 A CL 200800442A CL 2008000442 A CL2008000442 A CL 2008000442A CL 2008000442 A1 CL2008000442 A1 CL 2008000442A1
Authority
CL
Chile
Prior art keywords
micosis
chitosan
cosmetic
diseases
active ingredient
Prior art date
Application number
CL200800442A
Other languages
English (en)
Inventor
Federico Legora Miche Mailland
Original Assignee
Polichem Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38171596&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2008000442(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Polichem Sa filed Critical Polichem Sa
Publication of CL2008000442A1 publication Critical patent/CL2008000442A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/736—Chitin; Chitosan; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/02—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings containing insect repellants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Birds (AREA)
  • Molecular Biology (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL200800442A 2007-02-15 2008-02-12 Composicion farmaceutica que comprende a un quitosano, un ingrediente activo cosmetico o farmaceutico, y un solvente volatil; y su uso para tratar psoriasis, micosis entre otras enfermedades. CL2008000442A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90140507P 2007-02-15 2007-02-15
EP07102449A EP1958613A1 (en) 2007-02-15 2007-02-15 Dermal film-forming liquid formulations for drug release to skin

Publications (1)

Publication Number Publication Date
CL2008000442A1 true CL2008000442A1 (es) 2008-08-22

Family

ID=38171596

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200800442A CL2008000442A1 (es) 2007-02-15 2008-02-12 Composicion farmaceutica que comprende a un quitosano, un ingrediente activo cosmetico o farmaceutico, y un solvente volatil; y su uso para tratar psoriasis, micosis entre otras enfermedades.

Country Status (22)

Country Link
US (1) US20100062083A1 (es)
EP (2) EP1958613A1 (es)
JP (1) JP5376372B2 (es)
KR (1) KR20090119878A (es)
CN (2) CN103751790A (es)
AR (1) AR065318A1 (es)
BR (1) BRPI0721305A2 (es)
CA (1) CA2675568C (es)
CL (1) CL2008000442A1 (es)
CO (1) CO6210803A2 (es)
EA (1) EA019102B1 (es)
EC (1) ECSP099635A (es)
IL (2) IL199841A (es)
MA (1) MA31238B1 (es)
ME (1) ME00829B (es)
MX (1) MX2009008515A (es)
MY (1) MY161895A (es)
NO (1) NO20092998L (es)
NZ (1) NZ578611A (es)
UA (1) UA97134C2 (es)
WO (1) WO2008098634A1 (es)
ZA (1) ZA200904945B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2450133T3 (es) 2003-01-24 2014-03-24 Stiefel Research Australia Pty Ltd Espuma de fosfato de clindamicina
EP2153836A1 (en) * 2008-08-04 2010-02-17 Polichem S.A. Film-forming liquid formulations for drug release to hair and scalp
EP2116237A1 (en) * 2008-08-05 2009-11-11 Polichem SA Compositions for treating rosacea comprising chitosan and a dicarboxylic acid
DK2400951T3 (en) 2009-02-25 2018-12-03 Mayne Pharma Llc TOPICAL FOAM COMPOSITION
BRPI1009982A2 (pt) 2009-05-01 2017-06-27 Signal Investment & Man Co composição antimicrobiana hidratante
WO2011024168A2 (en) * 2009-08-26 2011-03-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd Sustained release delivery systems for the prevention and treatment of head and neck cancers
JP5833007B2 (ja) * 2009-08-31 2015-12-16 ドクター・レディーズ・ラボラトリーズ・リミテッド ステロイドを含む局所製剤
LT2482822T (lt) 2009-10-01 2018-09-10 Adare Pharmaceuticals, Inc. Geriamosios kortikosteroidų kompozicijos
GB2477768A (en) * 2010-02-12 2011-08-17 Chao-Ho Liu Pharmaceutical material for treating psoriasis
CN103269702A (zh) * 2010-11-04 2013-08-28 442合资有限责任公司 用于治疗皮肤病的组合物和方法
CN102210746B (zh) * 2011-04-08 2012-11-07 福建美菰林生物科技有限公司 治疗足部真菌感染的乳膏药物组合物及其制备方法
KR101470087B1 (ko) * 2011-11-22 2014-12-10 동국대학교 산학협력단 면역억제제 및 트랜스글루타미나제 ２ 억제제를 포함하는 아토피 피부염의 예방, 치료 또는 개선용 조성물
CN110075310A (zh) * 2011-12-20 2019-08-02 维奥姆治疗有限公司 用于治疗真菌感染的局部油组合物
US8697753B1 (en) 2013-02-07 2014-04-15 Polichem Sa Method of treating onychomycosis
WO2015034678A2 (en) 2013-09-06 2015-03-12 Aptalis Pharmatech, Inc. Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis
DK3089737T3 (da) 2013-12-31 2021-12-13 Rapamycin Holdings Llc Orale rapamycin-nanopartikelpræparater og anvendelse.
CN106551931A (zh) * 2016-04-11 2017-04-05 张梦兮 1-羟基-2-吡啶酮类化合物在制备口腔黏膜疾病治疗药物上的用途
JP6660258B2 (ja) * 2016-06-20 2020-03-11 ライオン株式会社 制汗剤組成物
TWI728172B (zh) 2016-08-18 2021-05-21 美商愛戴爾製藥股份有限公司 治療嗜伊紅性食道炎之方法
JP2022127602A (ja) * 2021-02-19 2022-08-31 アース製薬株式会社 噴霧された粒子の収縮を抑制する方法
CN120478204A (zh) * 2025-06-20 2025-08-15 诺德溯源(广州)生物科技有限公司 一种智能缓解须后刺激的舒缓修护组合物及应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1170188A (en) * 1967-09-15 1969-11-12 Bayer Ag N-trityl-imidazoles and salts and uses thereof
US4117118A (en) * 1976-04-09 1978-09-26 Sandoz Ltd. Organic compounds
IL73534A (en) * 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
DE3421363A1 (de) * 1984-06-08 1985-12-12 Bayer Ag, 5090 Leverkusen Verfahren und vorrichtung zum kontinuierlichen herstellen von gegenstaenden oder beschichtungen mit kompliziert geformten konturen
US4822604A (en) * 1985-05-20 1989-04-18 S. C. Johnson & Son, Inc. Local treatment of dandruff, seborrheic dermatitis, and psoriasis
DE3541305A1 (de) * 1985-11-22 1987-05-27 Wella Ag Kosmetische mittel auf der basis von n-hydroxypropylchitosanen, neue n-hydroxypropyl-chitosane sowie verfahren zu ihrer herstellung
US4946870A (en) * 1986-06-06 1990-08-07 Union Carbide Chemicals And Plastics Company Inc. Delivery systems for pharmaceutical or therapeutic actives
US5300494A (en) * 1986-06-06 1994-04-05 Union Carbide Chemicals & Plastics Technology Corporation Delivery systems for quaternary and related compounds
AU643058B2 (en) * 1990-08-30 1993-11-04 Terumo Kabushiki Kaisha Wound-covering materials
JPH0543480A (ja) * 1991-08-08 1993-02-23 Nippon Soda Co Ltd 活性ペプタイド含有キトサン誘導体フイルム剤
JPH05339152A (ja) * 1992-06-09 1993-12-21 Nippon Soda Co Ltd 皮膚病変局所投与薬剤含有キトサン誘導体フィルム剤
GB9411530D0 (en) * 1994-06-09 1994-08-03 Quayle Rachel A Use of polymers as film-forming barrier materials
SE9402531L (sv) * 1994-07-19 1996-01-20 Medicarb Ab Sårläkningsmedel
SE9604610D0 (sv) * 1996-12-16 1996-12-16 Noviscens Ab Medical composition
US6231875B1 (en) * 1998-03-31 2001-05-15 Johnson & Johnson Consumer Companies, Inc. Acidified composition for topical treatment of nail and skin conditions
DE10035991A1 (de) * 2000-07-24 2002-02-14 Polichem Sa Nagellackzusammensetzung
EP1179352A1 (en) * 2000-08-08 2002-02-13 MONTERESEARCH S.r.l. Topical composition for covering a skin lesion
CA2431236A1 (en) * 2001-01-09 2002-07-18 Israel Dvoretzky Therapeutic film forming composition and treatment system
US7297343B2 (en) * 2001-07-31 2007-11-20 Biosurface Engineering Technologies, Inc. Bioactive medical films
AU2002950506A0 (en) * 2002-07-31 2002-09-12 Soltec Research Pty Ltd Percutaneous delivery system
EP1491202A1 (en) * 2003-06-23 2004-12-29 Polichem S.A. Nail restructuring compositions for topical application
JP2005281654A (ja) * 2004-03-31 2005-10-13 Rikogaku Shinkokai 温度応答性組成物およびそのヒドロゲル

Also Published As

Publication number Publication date
JP2010518130A (ja) 2010-05-27
KR20090119878A (ko) 2009-11-20
NZ578611A (en) 2012-08-31
IL241166A0 (en) 2015-11-30
CA2675568A1 (en) 2008-08-21
US20100062083A1 (en) 2010-03-11
MX2009008515A (es) 2009-08-20
AU2007346756A1 (en) 2008-08-21
AR065318A1 (es) 2009-05-27
NO20092998L (no) 2009-09-14
ZA200904945B (en) 2010-09-29
CN103751790A (zh) 2014-04-30
BRPI0721305A2 (pt) 2014-03-25
IL199841A0 (en) 2010-04-15
AU2007346756A2 (en) 2009-09-24
EP1958613A1 (en) 2008-08-20
JP5376372B2 (ja) 2013-12-25
WO2008098634A1 (en) 2008-08-21
IL199841A (en) 2015-09-24
CA2675568C (en) 2015-05-12
CO6210803A2 (es) 2010-10-20
ECSP099635A (es) 2010-03-31
MA31238B1 (fr) 2010-03-01
ME00829B (me) 2012-03-20
UA97134C2 (ru) 2012-01-10
EA019102B1 (ru) 2014-01-30
MY161895A (en) 2017-05-15
CN101641082A (zh) 2010-02-03
EP2117500A1 (en) 2009-11-18
EA200901112A1 (ru) 2010-02-26

Similar Documents

Publication Publication Date Title
CL2008000442A1 (es) Composicion farmaceutica que comprende a un quitosano, un ingrediente activo cosmetico o farmaceutico, y un solvente volatil; y su uso para tratar psoriasis, micosis entre otras enfermedades.
AR124134A2 (es) Formulación de uso tópico para un inhibidor de jak
CL2013001104A1 (es) Composicion farmaceutica que comprende un inhibidor de sglt2 y una insulina; y uso para tratar una enfermedad o afeccion tal como diabetes mellitus, diabetes mellitus tipo 1 y 2, entre otras.
CL2008001002A1 (es) Compuestos derivados de oxazolidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para preparar un medicamento para tratar una infeccion bacteriana.
BRPI0806531A2 (pt) Composto, composição farmacêutica, agente terapêutico, e, uso do composto.
CL2015001959A1 (es) (divisional solicitud 1567-2013) combinaciones de principios activos que comprenden piridiletilbenzamidas y otros principios activos
CL2007003356A1 (es) Compuestos derivados de benzopirazoles; proceso para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos y otro agente activo; y su uso para el tratamiento del asma, inflamacion, entre otras enfermedades.
CL2008000691A1 (es) Compuestos derivados de dihidro y tetrahidro oxazolopirimidinonas sustituidas; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de la esquizofrenia, epilepsia, entre otras enfermedades.
AR059545A1 (es) Combinacion de verbacosido y luteolina
CL2008000593A1 (es) Uso de compuestos derivados de heterociclos sustituidos; composicion farmaceutica que comprende a dichos compuestos y otros agentes activos; y su uso para tratar diabetes, enfermedad aterosclerotica de las arterias entre otras enfermedades.
ES2409069R1 (es) Uso de aglutinantes para fabricar formulaciones estables al almacenamiento
AR072685A1 (es) Composicion topica para el tratamiento de queratosis actinica
BRPI0815577A2 (pt) Peptídeo foxm1 e agente medicinal compreendendo o mesmo.
CR20110599A (es) Composiciones farmacéuticamente activas que comprenden moduladores de estrés oxidativo (osm), nuevas entidades químicas, composiciones y usos
BR112015018087A8 (pt) composto, composição farmacêutica e uso
CL2014003225A1 (es) Composición que comprende un agente de control biológico y un fungicida.
CL2008000594A1 (es) Uso de compuestos derivados de heterociclos; composicion farmaceutica que comprende a dichos compuestos y otros agentes activos; y su uso para tratar diabetes, enfermedad arterial coronaria entre otras enfermedades.
WO2010021607A3 (en) Pharmaceutical formulation
CL2008000610A1 (es) Composicion en forma de dosificacion transdermica o transmucosa que comprende una relacion en peso de buprenorfina a naloxona entre 2,1:1 y 8:1, util para el tratamiento del dolor.
AR046642A1 (es) Composicion en forma de spray que comprende un activo farmaceutico, al menos una silicona volatil y una fase aceitosa, no volatil
CL2011002675A1 (es) Uso de compuestos derivados de nitrato o sulfato de 9-purin-9-il-3,4-dihidroxitetrahidrofuran-2-il-metilo para reducir la presion intraocular ; composicion farmaceutica oftalmica que comprende los compuestos; y formulacion oftalmica de uso topico que los comprende.
NI201200157A (es) Composiciones farmacéuticas que comprenden hidromorfona y naloxona
CL2014003081A1 (es) Una composicion farmaceutica topica que comprende, en base al peso total de la composicion, 1,5-5 % en peso de terbinafina, 15-35 % en peso de urea y mas que 25 % en peso de agua; y su uso para el tratamiento topico de una infeccion fungica, preferiblemente onicomicosis.
CL2013001411A1 (es) Peptido que posee actividad antiapoptotica; conjugado que lo comprende; composicion farmaceutica que lo comprende; y su uso para tratar una enfermedad o condicion asociada con apoptosis en un sujeto.
CL2009001841A1 (es) Uso de una composición de liberación sostenida de 4-aminopiridina para preparar un medicamento útil para tratar esclerosis multiple en un sujeto.